SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-24-104862
Filing Date
2024-04-22
Accepted
2024-04-22 16:11:57
Documents
7
Period of Report
2024-06-04

Document Format Files

Seq Description Document Type Size
1 DEF 14A d454010ddef14a.htm DEF 14A 435862
2 GRAPHIC g454010g02k01.jpg GRAPHIC 30082
3 GRAPHIC g454010g02k02.jpg GRAPHIC 20413
4 GRAPHIC g454010g37k01.jpg GRAPHIC 51423
5 GRAPHIC g454010g37k02.jpg GRAPHIC 49369
6 GRAPHIC g454010g44k01.jpg GRAPHIC 155745
7 GRAPHIC g454010g44k02.jpg GRAPHIC 144312
  Complete submission text file 0001193125-24-104862.txt   1053775
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36332 | Film No.: 24861327
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)